Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review.


Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
09 2020
Historique:
received: 20 03 2020
revised: 19 06 2020
accepted: 20 06 2020
pubmed: 28 6 2020
medline: 19 5 2021
entrez: 28 6 2020
Statut: ppublish

Résumé

Diagnosing heart failure with preserved ejection fraction (HFpEF) in the non-acute setting remains challenging. Natriuretic peptides have limited value for this purpose, and a multitude of studies investigating novel diagnostic circulating biomarkers have not resulted in their implementation. This review aims to provide an overview of studies investigating novel circulating biomarkers for the diagnosis of HFpEF and determine their risk of bias (ROB). A systematic literature search for studies investigating novel diagnostic HFpEF circulating biomarkers in humans was performed up until 21 April 2020. Those without diagnostic performance measures reported, or performed in an acute heart failure population were excluded, leading to a total of 28 studies. For each study, four reviewers determined the ROB within the QUADAS-2 domains: patient selection, index test, reference standard, and flow and timing. At least one domain with a high ROB was present in all studies. Use of case-control/two-gated designs, exclusion of difficult-to-diagnose patients, absence of a pre-specified cut-off value for the index test without the performance of external validation, the use of inappropriate reference standards and unclear timing of the index test and/or reference standard were the main bias determinants. Due to the high ROB and different patient populations, no meta-analysis was performed. The majority of current diagnostic HFpEF biomarker studies have a high ROB, reducing the reproducibility and the potential for clinical care. Methodological well-designed studies with a uniform reference diagnosis are urgently needed to determine the incremental value of circulating biomarkers for the diagnosis of HFpEF.

Identifiants

pubmed: 32592317
doi: 10.1002/ejhf.1944
pmc: PMC7689920
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1586-1597

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

J Am Coll Cardiol. 2019 Mar 26;73(11):1300-1313
pubmed: 30898206
J Am Coll Cardiol. 2017 Jun 27;69(25):3119-3121
pubmed: 28641802
Eur J Echocardiogr. 2009 Mar;10(2):165-93
pubmed: 19270053
JAMA Cardiol. 2018 Dec 1;3(12):1206-1210
pubmed: 30383171
JAMA. 1999 Sep 15;282(11):1061-6
pubmed: 10493205
Ann Intern Med. 2004 Feb 3;140(3):189-202
pubmed: 14757617
ESC Heart Fail. 2018 Apr;5(2):372-378
pubmed: 29345112
Heart Lung Circ. 2016 Oct;25(10):1000-6
pubmed: 27067668
JACC Heart Fail. 2017 Aug;5(8):575-577
pubmed: 28711450
Am J Med. 2001 Jun 15;110(9):681-6
pubmed: 11403751
Eur J Heart Fail. 2020 May;22(5):775-788
pubmed: 32220046
Circulation. 2006 May 16;113(19):2335-62
pubmed: 16702488
Eur J Heart Fail. 2012 Nov;14(11):1240-8
pubmed: 22843563
Am J Cardiol. 2012 Sep 15;110(6):870-6
pubmed: 22681864
J Am Coll Cardiol. 2002 Sep 4;40(5):976-82
pubmed: 12225726
Clin Chem. 2008 Apr;54(4):729-37
pubmed: 18258670
Circ Heart Fail. 2011 May;4(3):246-56
pubmed: 21350055
Eur J Heart Fail. 2012 Dec;14(12):1338-47
pubmed: 22869458
Int J Cardiol. 2017 Jan 15;227:272-277
pubmed: 27838133
Nat Rev Cardiol. 2016 Jun;13(6):368-78
pubmed: 26935038
Med Sci Monit. 2018 Jul 24;24:5139-5146
pubmed: 30039808
JAMA. 2018 Jan 23;319(4):388-396
pubmed: 29362800
Circulation. 2016 Jul 5;134(1):73-90
pubmed: 27358439
JACC Heart Fail. 2017 Feb;5(2):92-98
pubmed: 28017355
Eur J Heart Fail. 2009 Feb;11(2):191-7
pubmed: 19168518
Ann Intern Med. 2011 Oct 18;155(8):529-36
pubmed: 22007046
Eur J Heart Fail. 2015 Apr;17(4):405-15
pubmed: 25739750
PLoS One. 2013;8(1):e53560
pubmed: 23326457
Circulation. 2017 Jul 4;136(1):6-19
pubmed: 28381470
Clin Chem. 2005 Aug;51(8):1335-41
pubmed: 15961549
J Cell Mol Med. 2014 Nov;18(11):2189-97
pubmed: 25124701
Eur J Heart Fail. 2018 Aug;20(8):1205-1214
pubmed: 29855124
J Cardiovasc Transl Res. 2017 Jun;10(3):233-244
pubmed: 28585183
Eur J Heart Fail. 2015 Apr;17(4):393-404
pubmed: 25619197
Biomark Med. 2019 Jun;13(9):737-750
pubmed: 31157550
Card Fail Rev. 2019 Feb;5(1):44-49
pubmed: 30847245
Circulation. 2018 Jan 30;137(5):534-535
pubmed: 29378762
Acta Cardiol. 2016 Apr;71(2):191-7
pubmed: 27090041
Eur J Heart Fail. 2015 Oct;17(10):1006-14
pubmed: 26472682
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Nat Rev Cardiol. 2017 Oct;14(10):591-602
pubmed: 28492288
Res Pract Thromb Haemost. 2018 Oct 26;3(1):49-58
pubmed: 30656276
J Card Fail. 2013 Mar;19(3):163-8
pubmed: 23482076
EBioMedicine. 2016 Jan 20;4:86-94
pubmed: 26981573
Cardiovasc Diabetol. 2016 Oct 3;15(1):140
pubmed: 27716206
BMC Cardiovasc Disord. 2016 Oct 21;16(1):199
pubmed: 27769173
Heart Lung. 2020 Jul - Aug;49(4):388-392
pubmed: 32145960
Eur J Heart Fail. 2010 Dec;12(12):1309-16
pubmed: 20837635
J Clin Epidemiol. 2013 Oct;66(10):1093-104
pubmed: 23958378
Eur Heart J Cardiovasc Imaging. 2016 Dec;17(12):1321-1360
pubmed: 27422899
Kaohsiung J Med Sci. 2012 Mar;28(3):165-72
pubmed: 22385610
Neth Heart J. 2016 Apr;24(4):252-8
pubmed: 26942916
PLoS One. 2015 May 26;10(5):e0124844
pubmed: 26010610
Cardiology. 2019;143(3-4):77-84
pubmed: 31466059
ESC Heart Fail. 2017 Aug;4(3):301-311
pubmed: 28772032
Clin Res Cardiol. 2019 Sep;108(9):1025-1033
pubmed: 30788622
Genomics Proteomics Bioinformatics. 2014 Jun;12(3):120-6
pubmed: 24508280
J Clin Epidemiol. 2003 Sep;56(9):826-32
pubmed: 14505766
Int J Cardiol. 2018 Nov 15;271:132-139
pubmed: 30482453
Circ Res. 2018 Aug 17;123(5):614-629
pubmed: 30355136
JACC Heart Fail. 2014 Oct;2(5):477-88
pubmed: 24929535
Circ Heart Fail. 2010 Sep;3(5):588-95
pubmed: 20543134
Eur Heart J. 2007 Oct;28(20):2539-50
pubmed: 17428822
Neth Heart J. 2016 Apr;24(4):287-95
pubmed: 26940695
J Am Coll Cardiol. 2013 Jul 23;62(4):263-71
pubmed: 23684677
Eur Heart J. 2019 Oct 21;40(40):3297-3317
pubmed: 31504452
Circulation. 2018 Aug 28;138(9):861-870
pubmed: 29792299
Crit Rev Clin Lab Sci. 2018 Jun;55(4):246-263
pubmed: 29663841
Echocardiography. 2019 Jun;36(6):1074-1083
pubmed: 31162738
Am J Physiol Heart Circ Physiol. 2018 Dec 1;315(6):H1670-H1683
pubmed: 30239232

Auteurs

Michiel T H M Henkens (MTHM)

Department of Cardiology, Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands.

Sharon Remmelzwaal (S)

Department of Epidemiology and Biostatistics, Amsterdam Cardiovascular Sciences Research Institute, Amsterdam UMC, Amsterdam, The Netherlands.

Emma L Robinson (EL)

Department of Cardiology, Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands.

Adriana J van Ballegooijen (AJ)

Department of Epidemiology and Biostatistics, Amsterdam Cardiovascular Sciences Research Institute, Amsterdam UMC, Amsterdam, The Netherlands.

Arantxa Barandiarán Aizpurua (A)

Department of Cardiology, Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands.

Job A J Verdonschot (JAJ)

Department of Cardiology, Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands.
Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.

Anne G Raafs (AG)

Department of Cardiology, Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands.

Jerremy Weerts (J)

Department of Cardiology, Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands.

Mark R Hazebroek (MR)

Department of Cardiology, Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands.

Sandra Sanders-van Wijk (S)

Department of Cardiology, Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands.

M Louis Handoko (ML)

Department of Cardiology, Amsterdam Cardiovascular Sciences Research Institute, Amsterdam UMC, Amsterdam, The Netherlands.

Hester M den Ruijter (HM)

Laboratory of Experimental Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Carolyn S P Lam (CSP)

National Heart Centre Singapore, Singapore, Singapore.
Duke-National University of Singapore, Singapore, Singapore.
Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Rudolf A de Boer (RA)

Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Walter J Paulus (WJ)

Department of Physiology, Amsterdam Cardiovascular Sciences Research Institute, Amsterdam UMC, Amsterdam, The Netherlands.
Netherlands Heart Institute (ICIN), Utrecht, The Netherlands.

Vanessa P M van Empel (VPM)

Department of Cardiology, Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands.

Rein Vos (R)

Department of Methodology and Statistics, Maastricht University, Maastricht, The Netherlands.

Hans-Peter Brunner-La Rocca (HP)

Department of Cardiology, Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands.

Joline W J Beulens (JWJ)

Department of Epidemiology and Biostatistics, Amsterdam Cardiovascular Sciences Research Institute, Amsterdam UMC, Amsterdam, The Netherlands.
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

Stephane R B Heymans (SRB)

Department of Cardiology, Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands.
Netherlands Heart Institute (ICIN), Utrecht, The Netherlands.
Department of Cardiovascular Research, University of Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH